Making 'sense' of diabetes: Using a continuous glucose sensor in clinical practice

Authors: Cheyne, E., Kerr, D.

Journal: Diabetes Metabolism Research and Reviews

Publication Date: 30/04/2002

Volume: 18

Issue: SUPPL. 1

Pages: S43-S48

ISSN: 1520-7552

DOI: 10.1002/dmrr.209

Abstract:

Home blood glucose monitoring provides only a snapshot picture of prevailing glucose values. Continuous glucose monitoring allows identification of patterns of glucose levels for up to 72 h with details of excursions above and below target levels and thus may be a valuable adjunct tool in diabetes management. We have used the MiniMed Continuous Glucose Monitoring System (CGMS) in ten individuals and have uncovered a significant rate of hypoglycaemia that was previously undetected by conventional means. Preliminary evidence suggests that the novel technology may allow clinicians to 'personalise' intensive insulin therapy with improvement in glycaemic control. Copyright © 2002 John Wiley & Sons, Ltd.

Source: Scopus

Making 'sense' of diabetes: using a continuous glucose sensor in clinical practice.

Authors: Cheyne, E., Kerr, D.

Journal: Diabetes Metab Res Rev

Publication Date: 2002

Volume: 18 Suppl 1

Pages: S43-S48

ISSN: 1520-7552

DOI: 10.1002/dmrr.209

Abstract:

Home blood glucose monitoring provides only a snapshot picture of prevailing glucose values. Continuous glucose monitoring allows identification of patterns of glucose levels for up to 72 h with details of excursions above and below target levels and thus may be a valuable adjunct tool in diabetes management. We have used the MiniMed Continuous Glucose Monitoring System (CGMS) in ten individuals and have uncovered a significant rate of hypoglycaemia that was previously undetected by conventional means. Preliminary evidence suggests that the novel technology may allow clinicians to 'personalise' intensive insulin therapy with improvement in glycaemic control.

Source: PubMed

Making 'sense' of diabetes: using a continuous glucose sensor in clinical practice

Authors: Cheyne, E., Kerr, D.

Journal: DIABETES-METABOLISM RESEARCH AND REVIEWS

Publication Date: 2002

Volume: 18

Pages: S43-S48

eISSN: 1520-7560

ISSN: 1520-7552

DOI: 10.1002/dmrr.209

Source: Web of Science

Making 'sense' of diabetes: using a continuous glucose sensor in clinical practice

Authors: Cheyne, E.H., Kerr, D.

Journal: Diabetes/Metabolism Research and Reviews

Publication Date: 2002

Volume: 18

Pages: S43-S48

ISSN: 1520-7552

DOI: 10.1002/dmrr.209

Abstract:

Home blood glucose monitoring provides only a snapshot picture of prevailing glucose values. Continuous glucose monitoring allows identification of patterns of glucose levels for up to 72 h with details of excursions above and below target levels and thus may be a valuable adjunct tool in diabetes management. We have used the MiniMed Continuous Glucose Monitoring System (CGMS) in ten individuals and have uncovered a significant rate of hypoglycaemia that was previously undetected by conventional means. Preliminary evidence suggests that the novel technology may allow clinicians to personalise intensive insulin therapy with improvement in glycaemic control.

http://www3.interscience.wiley.com/cgi-bin/abstract/91016184/ABSTRACT?CRETRY=1&SRETRY=0

Source: Manual

Preferred by: David Kerr

Making 'sense' of diabetes: using a continuous glucose sensor in clinical practice.

Authors: Cheyne, E., Kerr, D.

Journal: Diabetes/metabolism research and reviews

Publication Date: 01/2002

Volume: 18 Suppl 1

Pages: S43-S48

eISSN: 1520-7560

ISSN: 1520-7552

DOI: 10.1002/dmrr.209

Abstract:

Home blood glucose monitoring provides only a snapshot picture of prevailing glucose values. Continuous glucose monitoring allows identification of patterns of glucose levels for up to 72 h with details of excursions above and below target levels and thus may be a valuable adjunct tool in diabetes management. We have used the MiniMed Continuous Glucose Monitoring System (CGMS) in ten individuals and have uncovered a significant rate of hypoglycaemia that was previously undetected by conventional means. Preliminary evidence suggests that the novel technology may allow clinicians to 'personalise' intensive insulin therapy with improvement in glycaemic control.

Source: Europe PubMed Central